Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02474199 · ClinicalTrials.gov registry record · Phase 1
Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02474199 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 15 participants.
The verdict
NCT02474199, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This research study is for liver transplant recipients and their respective living donors. The purpose of this study is: 1. To see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells (Tregs) 2. To see if the Tregs allows a liver recipient to take less, or completely stop medications normally taken after receiving an organ transplant.
Interventions
- DRUG Acetaminophen
- DRUG Diphenhydramine
- BIOLOGICAL darTregs
- DRUG Immunosuppression (IS) Withdrawal
- PROCEDURE Study Mandated Procedures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-06-06 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02474199
The ClinicalTrials.gov registry entry for NCT02474199 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Acetaminophen is the first listed.
NCT02474199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02474199 about?
NCT02474199 is a clinical study titled "Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction". This research study is for liver transplant recipients and their respective living donors. The purpose of this study is: 1. To see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells (Tregs) 2. To see if the Tregs allows a liver recipient to take less, or co...
What is the current status of trial NCT02474199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-06-06. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT02474199?
The interventions under investigation include: Acetaminophen (DRUG), Diphenhydramine (DRUG), darTregs (BIOLOGICAL), Immunosuppression (IS) Withdrawal (DRUG), Study Mandated Procedures (PROCEDURE).
Who is sponsoring clinical trial NCT02474199?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.